Brose, M. S., Panaseykin, Y., Konda, B., Fouchardiere, C. d. l., Hughes, B. G., Gianoukakis, A. G., . . . Taylor, M. H. (2022). A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer. ABV-press.
Chicago Style (17th ed.) CitationBrose, M. S., et al. A Randomized Study to Evaluate the Safety and Efficacy of Two Dosages of Lenvatinib – 18 and 24 Mg – in Patients with Radioiodrefract Differentiated Thyroid Cancer. ABV-press, 2022.
MLA (9th ed.) CitationBrose, M. S., et al. A Randomized Study to Evaluate the Safety and Efficacy of Two Dosages of Lenvatinib – 18 and 24 Mg – in Patients with Radioiodrefract Differentiated Thyroid Cancer. ABV-press, 2022.
Warning: These citations may not always be 100% accurate.